The filing is a routine VC distribution notice and does not indicate management concern. However, continued selling by Atlas entities could create near-term overhang. Monitor for further Form 144 filings or Form 4 filings to gauge the pace of distribution.
Price Chart
Executive Summary
Atlas Venture Fund X, L.P., a venture capital firm and early investor in Kymera Therapeutics, filed a Form 144 notice of intent to sell 118,178 shares of common stock, valued at approximately $11.6 million. This follows a series of large sales by Atlas entities in June 2026, totaling hundreds of thousands of shares, consistent with a venture fund distributing to limited partners. The proposed sale represents a small fraction (0.12%) of Kymera's $9.4B market cap and is not a signal of fundamental deterioration.
Key Facts
- Atlas Venture Fund X, L.P. filed a Form 144 to sell 118,178 shares of Kymera Therapeutics common stock.
- Estimated market value of the proposed sale is $11,610,988.50.
- Shares were acquired in a private placement on March 11, 2020.
- Atlas entities have sold over 450,000 shares in June 2026 alone, including 243,976 shares on June 22, 2026.
- The selling entity is a venture capital fund, not an executive insider.
Financial Impact
Proposed sale of 118,178 shares (~$11.6M) represents 0.12% of Kymera's $9.4B market cap.
Risk Factors
- Continued selling by Atlas Venture could pressure the stock in the short term.
- Large insider/affiliate sales may be misinterpreted by the market as a negative signal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-045290 |
| Document: 0001628280-26-045290-index.html | 0001628280-26-045290 |
| Document: 0001628280-26-045290.txt | 0001628280-26-045290 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $105.48 $118.63 | ▲ +12.47% | ▲ +13.07% | $107.39 (+1.81%) |
Jul 8, 2026 12w ago | Insider Cluster | $114.16 $105.48 | ▲ +7.60% | ▲ +10.88% | $107.39 (+5.93%) |
Jul 2, 2026 13w ago | Insider Cluster | $113.51 $107.01 | ▲ +5.73% | ▲ +5.31% | $107.39 (+5.39%) |
Jul 2, 2026 13w ago | Insider Cluster | $113.51 $107.01 | ▲ +5.73% | ▲ +5.31% | $107.39 (+5.39%) |
Jun 30, 2026 13w ago | 144 | $114.20 $105.25 | ▲ +7.84% | ▲ +5.65% | $107.39 (+5.96%) |
Jun 29, 2026 13w ago | 144 | $114.67 $110.05 | ▼ −4.03% | ▼ −3.00% | $107.39 (−6.35%) |
Jun 26, 2026 14w ago | Insider Cluster | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 26, 2026 14w ago | 144 | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 26, 2026 14w ago | 144 | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 24, 2026 14w ago | 144 | $116.46 $110.38 | ▼ −5.22% | ▼ −5.75% | $107.39 (−7.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access